comprehensive -WSS

comprehensive

author：focus 2025-08-23 08:53:09 - browse：211

Light hits on the portrait of George Washington on a one dollar bill. The portrait is surrounded by white and red tablets coming out of a pill bottle, as well as some coins — coverage from STAT — Adobe

WASHINGTON — Pharmaceutical companies are doing anything they can to stop President Biden’s Medicare program from being able to negotiate prices for their products, including suing the government. Experts say their efforts might actually benefit Biden by reminding voters that he’s taking on big drug companies.

When Democrats passed a law directing Medicare to negotiate drug prices, it was considered a major achievement. The new law, two decades in the making, gives Biden an accomplishment to both tout for himself and criticize Republicans for opposing — no Republicans voted to let Medicare negotiate drug prices.

Medicare price negotiation is popular with voters, as are the law’s price-inflation limits, and it includes additional, direct benefits for older adults that are easy to understand. It caps annual out-of-pocket retail-drug spending for seniors and people with disabilities, and it caps their monthly spending on insulin at $35.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Why health records don't always know when patients are dead

leisure time

focus

WSS

First Opinion on colorectal cancer screening: letter and response

Christmas in the PICU brings some surprising joy

People with mental disorders often marry others with same

Three trends to watch in biotech in 2024

Pancreatic cancer is often deadly, but new discoveries are raising hope

Editas, Vertex strike deal on CRISPR

hotspot

comprehensive

hotspot

State Dept. review finds Biden bears some blame for Afghanistan failures

Violet CEO on training clinicians to promote more inclusive care

United colonoscopy coverage change 'may cost lives,' doctors say

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Medicare details structure of new drug price negotiation program

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Medicare details structure of new drug price negotiation program

Oral obesity drug from Viking Therapeutics hits key early target

How one medical school became remarkably diverse

Insurer loopholes limit power of law against surprise medical bills

knowledge

Prime Medicine, Myeloid Therapeutics clash over genome

Can sheer will power keep patients alive in their dying hours?

Why health records don't always know when patients are dead

Bird flu in dairy cattle: New measures to control spread to humans

Overprescribed: High cost isn't America's only drug problem

Covid silver lining: Unprecedented look at human immune system

focus

leisure time

focus

hotspot